Arcturus Therapeutics Holdings Inc. (ARCT)
ARCT moved a median of -0.51% 30 minutes after news, and -0.75% by the close. How ARCT actually reacts to news — the realized, point-in-time move the market made, measured across 281 labeled events over the last three years with zero look-ahead.
ARCT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 48% | 280 |
| 30-min | -0.51% | 36% | 281 |
| 60-min | -0.22% | 47% | 281 |
| to close | -0.75% | 44% | 275 |
| Middle 50% of ARCT reactions | -1.46% to +0.67% |
|---|---|
| Median reaction (30-min) | -0.51% |
| Measured reactions | 281 |
Half of all Arcturus Therapeutics Holdings Inc. news events land between -1.46% and +0.67% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ARCT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | -0.57% | 40% | +6.10% |
| Coverage initiations | 23 | -0.94% | 13% | -1.17% |
| Rating reiterations | 71 | -0.59% | 34% | -0.93% |
| Price-target cuts | 15 | 0.00% | 47% | +0.35% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ARCT ranks against every other measured name →
That’s how ARCT usually reacts — get an email when it moves on news →Email me when ARCT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARCT's baseline. Nothing else.
Recent ARCT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Arcturus Therapeutics to Participate in Upcoming Investor Conferences | Press release | Business Wire | +5.51% | +9.11% | |
| Form 8-K Arcturus Therapeutics For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | +3.48% | +8.66% | |
| Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress | Press release | Business Wire | +1.07% | +13.82% | |
| Form 10-Q Arcturus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.07% | +13.82% | |
| Form 8-K Arcturus Therapeutics For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +13.82% | |
| Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 | Press release | Business Wire | +0.52% | +0.70% | |
| Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference | Press release | Business Wire | -0.17% | +0.34% | |
| Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis | Press release | Business Wire | +7.24% | -0.55% | |
| Form 8-K Arcturus Therapeutics For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +7.24% | -0.55% | |
| Form 8-K Arcturus Therapeutics For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | -3.52% | |
| Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference | Press release | Business Wire | +1.52% | +5.66% | |
| Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress | Press release | Business Wire | -0.36% | +12.16% | |
| Form 10-Q Arcturus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.36% | +12.16% | |
| Form 8-K Arcturus Therapeutics For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | +12.16% | |
| Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 | Press release | Business Wire | +1.81% | +6.87% | |
| Form DEF 14A Arcturus Therapeutics For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | +1.40% | -3.26% | |
| Arcturus Therapeutics to Attend Upcoming Investor Conference | Press release | Business Wire | -0.95% | -2.03% | |
| Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress | Press release | Business Wire | -6.33% | +0.93% | |
| Form 10-K Arcturus Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.33% | +0.93% | |
| Form 8-K Arcturus Therapeutics For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -6.33% | +0.93% | |
| Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 | Press release | Business Wire | -0.41% | +1.62% | |
| Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.95% | -1.02% | |
| Form S-3 Arcturus Therapeutics | SEC filing · Form S-3 | SEC EDGAR | +0.66% | +0.49% | |
| Form 8-K Arcturus Therapeutics For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | -1.63% | |
| Arcturus Therapeutics to Attend Upcoming Investor Conference | Press release | Business Wire | -0.16% | +5.75% | |
| Form 10-Q Arcturus Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.06% | -5.36% | |
| Form NT 10-Q Arcturus Therapeutics For: Sep 30 | SEC filing · Form NT | SEC EDGAR | +0.06% | -5.36% | |
| Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress | Press release | Business Wire | +3.89% | -2.03% | |
| Form 8-K Arcturus Therapeutics For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +3.89% | -2.03% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arcturus Therapeutics Holdings Inc. (ARCT) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +1.04% | +6.80% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Arcturus Therapeutics Holdings Inc. (ARCT) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.23% | -0.69% | |
| Arcturus Therapeutics to Attend Upcoming Investor Conferences | Press release | Business Wire | -0.67% | -3.79% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Arcturus Therapeutics Holdings Inc. (ARCT) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.87% | -4.55% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Arcturus Therapeutics Holdings Inc. (ARCT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.89% | -7.83% | |
| Arcturus Therapeutics Holdings Inc. (ARCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.26% | -1.23% | |
| Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 | Press release | Business Wire | -1.50% | -4.93% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arcturus Therapeutics Holdings Inc. (ARCT) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.97% | -3.98% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Arcturus Therapeutics Holdings Inc. (ARCT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.32% | -3.55% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arcturus Therapeutics Holdings Inc. (ARCT) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.36% | +1.72% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Arcturus Therapeutics Holdings Inc. (ARCT) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +1.63% | +2.83% | |
| Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program | Press release | Business Wire | -0.61% | +16.57% | |
| Form 8-K Arcturus Therapeutics For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | -0.61% | +16.57% | |
| Form 8-K Arcturus Therapeutics For: Sep 26 | SEC filing · Form 8-K | SEC EDGAR | +1.75% | +7.88% | |
| Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth | Press release | PR Newswire | +0.06% | +4.02% | |
| Form 8-K Arcturus Therapeutics For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | +1.00% | -0.12% | |
| Arcturus Therapeutics to Attend Upcoming Investor Conferences | Press release | Business Wire | +1.11% | -1.65% | |
| Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress | Press release | Business Wire | +3.99% | — | |
| Form 10-Q Arcturus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.99% | — | |
| Form 8-K Arcturus Therapeutics For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +3.99% | — | |
| Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 | Press release | Business Wire | -2.20% | -0.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARCT section they belong to.
Where else ARCT is measured.
ARCT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GEMPHIRE THERAPEUTICS INC COMMON (GEMP) | 282 | -1.00% | 30% |
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
| Aclaris Therapeutics, Inc. (ACRS) | 280 | 0.00% | 48% |
| Anika Therapeutics Inc. (ANIK) | 280 | +0.05% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Arcturus Therapeutics Holdings Inc.'s median reaction calculated?
Every labeled ARCT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 281 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of ARCT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ARCT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.